FindTrial
Sign In

Clinical effects and early assessment of high intensity focused ultrasound combined with bevacizumab in the treatment of colorectal liver metastases

Clinical effects and early assessment of high intensity focused ultrasound combined with bevacizumab in the treatment of colorectal liver metastases

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900023502
Enrollment
Unknown
Registered
2019-05-31
Start date
2019-07-01
Completion date
Unknown
Last updated
2019-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

1:HIFU
2:bevacizumab
3:HIFU+bevacizumab

Sponsors

Huadong Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Pathology (surgical resection or colonoscopy) confirmed colorectal cancer;(2) Radical resection for colorectal cancer has been performed;(3) Intrahepatic metastasis is confirmed by intraoperative or imaging findings. (4) Of liver function child-pugh grades for A or B; (5) The cardiopulmonary function is normal; (6) HIFU was accepted voluntarily and showed clear indications.

Exclusion criteria

Exclusion criteria: (1) Cases with only serological or imaging findings;(2) Serious cardiopulmonary disease; (3) has HIFU contraindications.

Design outcomes

Primary

MeasureTime frame
complete remission, CR;progression free survival, PFS;—

Countries

China

Contacts

Public ContactYanfei Zhu

Huadong Hospital

zyfhdyy@outlook.com+86 18818056815

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026